A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis, Dermatology, Dermatology, Dermatology, Dermatology, Dermatology, Dermatology, Dermatology, Hair Loss |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/6/2019 |
| Start Date: | December 21, 2018 |
| End Date: | December 31, 2026 |
| Contact: | Laura Dalfonso |
| Email: | ldalfonso@targetpharmasolutions.com |
| Phone: | 9842340268 |
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients
being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions
(IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients
with IMISC within academic and community real-world practices in order to assess the safety
and effectiveness of current and future therapies.
being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions
(IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients
with IMISC within academic and community real-world practices in order to assess the safety
and effectiveness of current and future therapies.
Inclusion Criteria:
- 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated
Inflammatory Skin Conditions been prescribed any dermatologic treatment.
- 2. Participant has plans for future visits at the site for continued management of
IMISC.
Exclusion Criteria:
- 1. Inability to provide written informed consent/assent.
- 2. Subjects participating in any interventional study or trial for IMISC treatment
trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once
participation in the trial is complete. Note: Participants may be enrolled in other
registries or studies where IMISC treatment outcomes are observed and/or reported
(such as center-based registries).
We found this trial at
7
sites
603 Village Boulevard
West Palm Beach, Florida 33406
West Palm Beach, Florida 33406
Principal Investigator: Barry Kuttner, MD
Phone: 561-964-6664
Click here to add this to my saved trials
Forest Hills, New York 11375
Principal Investigator: Jeffrey Weinberg, MD
Phone: 718-459-0900
Click here to add this to my saved trials
Fort Smith, Arkansas 72916
Principal Investigator: Sandra Johnson, MD
Phone: 479-649-3376
Click here to add this to my saved trials
Indianapolis, Indiana 46256
Principal Investigator: Kenneth W Dawes, MD
Phone: 317-516-5030
Click here to add this to my saved trials
Lincoln, Nebraska 68502
Principal Investigator: Rodney S Basler, MD
Phone: 402-421-3335
Click here to add this to my saved trials
New York, New York 10012
Principal Investigator: Robert Buka, MD
Phone: 212-385-3700
Click here to add this to my saved trials
Scottsdale, Arizona 85255
Principal Investigator: Brenda LaTowsky, MD
Phone: 480-440-5985
Click here to add this to my saved trials